ReviewJournal of pharmaceutical analysis2023
Anti-inflammatory natural products modulate interleukins and their related signaling markers in inflammatory bowel disease: A systematic review.
Review in Journal of pharmaceutical analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Chemical Profiling ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Ameliorative effect of MPAF on DSS-induced ulcerative colitis mice.Molecular biology reports · 2026Article
- Therapeutic Potential of Kinkeliba (Molecules (Basel, Switzerland) · 2026Article
- 6-Gingerol ameliorates high-fat, high-sucrose diet-induced metabolic dysfunction and depressive-like behaviors by attenuating neuroinflammation and oxidative stress.Metabolic brain disease · 2026Article
- Phenolic and fatty acid profile and antioxidant activity ofOpen medicine (Warsaw, Poland) · 2026Article
- The Role of Anthocyanins in Cardiovascular Health: A Review.Current cardiology reviews · 2026Review
- Article
- HarnessingInternational journal of molecular sciences · 2025Review
- Spent Hop (Cells · 2025Article
- Plasmon-activated water enhances gut-barrier function and alleviates inflammation in a mouse model of ulcerative colitis.Experimental and therapeutic medicine · 2025Article
- Immunomodulatory effect of allium sativum in type 2 diabetes mellitus.World journal of experimental medicine · 2025Review
- Therapeutic potential and underlying mechanisms of phytoconstituents: emphasizing on resveratol, curcumin, quercetin, berberine, and hesperidin in ulcerative colitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Danggui Beimu Kushen Pill Alleviates Colitis-Induced Inflammation in Mice by Regulating the IL-6/IL-6R and IL-17A/IL-17RA Signaling Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Ginseng polysaccharides ameliorate DSS-induced inflammatory bowel disease by regulating gut microbiota in dogs.Frontiers in veterinary science · 2025Article
- Article
- Oral Anti-Inflammatory and Symbiotic Effects of Fermented Lingonberry Juice-Potential Benefits in IBD.Nutrients · 2024Review
- Anti-Neuroinflammatory Effect of Ombuin fromInternational journal of molecular sciences · 2024Article
- Interactions between Dietary Antioxidants, Dietary Fiber and the Gut Microbiome: Their Putative Role in Inflammation and Cancer.International journal of molecular sciences · 2024Review
- Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease.Science advances · 2024Article
- Anti-Inflammatory Effects ofFoods (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to identify in vivo studies investigating the potential of plant substances and their natural molecules in managing inflammatory bowel disease (IBD). Specifically, the objective is to examine the impact of these substances on interleukins and other key inflammatory signaling markers. Relevant articles published up to December 2022 were identified through a search of the PubMed, Scopus, Web of Science, and Embase databases. The search used keywords including "inflammatory bowel disease", "medicinal plants", "natural molecules", "anti-inflammatory", and "ulcerative colitis", and identified 1,878 potentially relevant articles, of which 89 were included in this review after completion of the selection process. This study provides preclinical data on natural products (NPs) that can potentially treat IBD, including ulcerative colitis. The main actions of these NPs relate to their effects on nuclear factor kappa B (NF-κB), the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway, the regulation of T helper 17/regulatory T cells balance, and oxidative stress. The ability of these NPs to inhibit intestinal inflammation appears to be dependent on lowering levels of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-17, via the Jun N-terminal kinase (JNK)1, NF-κβ-p65, and STAT3 pathways. In addition, NPs were shown to reduce oxidative stress and the severity of ulcerative colitis, as well as increase the activity of antioxidant enzymes. These actions suggest that NPs represent a promising treatment for IBD, and potentially have greater efficacy and safety than current treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.